CHP
AKBA icon

Cable Hill Partners’s Akebia Therapeutics AKBA Stock Holding History

Cable Hill Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-233
Closed -$2K – 770
2018
Q2 		$2K Hold
233
– – ﹤0.01% 815
2018
Q1 		$2K Sell
233
-352
-60% -$4.92K ﹤0.01% 809
2017
Q4 		$9K Hold
585
– – ﹤0.01% 588
2017
Q3 		$12K Sell
585
-1
-0.2% -$15 0.01% 521
2017
Q2 		$9K Sell
586
-3
-0.5% -$38 ﹤0.01% 417
2017
Q1 		$5K Buy
589
+510
+646% +$4.98K ﹤0.01% 527
2016
Q4 		$1K Sell
79
-573
-88% -$4.93K ﹤0.01% 680
2016
Q3 		$6K Sell
652
-48
-7% -$408 ﹤0.01% 521
2016
Q2 		$6K Hold
700
– – ﹤0.01% 459
2016
Q1 		$7K Buy
700
+79
+13% +$641 0.01% 409
2015
Q4 		$9K Buy
+621
New +$6.34K 0.01% 365

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cable Hill Partners's AKBA Position: Q3 2018 in Review

Cable Hill Partners sold out of Akebia Therapeutics (AKBA) in Q3 2018, closing a stake of 233 shares — an estimated $2K sold.

Cable Hill Partners first reported a position in AKBA in Q4 2015 and held it in 11 quarters. The position peaked at $12K in Q3 2017. 130 funds tracked by Wall St. Rank hold AKBA as of Q3 2018.

  • Cable Hill Partners reported no remaining Akebia Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Cable Hill Partners sold 233 Akebia Therapeutics shares in Q3 2018, an estimated $2K.
  • Cable Hill Partners first reported a position in Akebia Therapeutics in Q4 2015 and held it in 11 quarters.
  • Cable Hill Partners's Akebia Therapeutics position peaked at $12K in Q3 2017.
  • 130 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2018.

Based on Cable Hill Partners's 13F filing for Q3 2018, filed 14 Nov 2018.